TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: 28-Days Mortality
Endpoint domain: Mortality/survival
Primary endpoint: Correlation of capsule endoscopy CECDAI with CDAI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correlation of capsule endoscopy CECDAI with IBDQ
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: decrease of average 24-hr ambulatory systolic BP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: amount of glucose metabolized
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: metabolic clearance rate for insulin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: quantity of glucose metabolized per unit plasma insulin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rate of glucose appearance & disappearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Participants Achieving SVR24
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Discontinuing From Study Treatment Due to AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Colonic inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Area under the concentration-time curve (AUC) for Danoprevir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration-time curve (AUC) for Ritonavir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: End-of-Cycle 1 DLT rate
Endpoint domain: Adverse events/effects
Primary endpoint: Firefighter Work Limitation Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Short- Western Ontario Rotator Cuff Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain assessed by Wong-Baker FACES
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain assessed by Visual Analog Scale (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fear assessed by The Children's Fear Scale (CFS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Psychometric properties of POMI scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Rate of Orthodontic Tooth Movement [Difference in Little's Irregularity Index, mm/Day]
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Orthodontic Tooth Movement [Total % Change of Little's Irregularity Index]
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amputee Mobility Predictor with Prosthesis (AMPPRO)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 6 minute Timed Walk Test (6m TWT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 5 times Sit-to-Stand (5 times STS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tumor objective response rate (ORR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Progress of tendon healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative changes in cranial diffusion MR imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: deterioration of joint function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: dispnea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: skin rash
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Adverse events associated with EGFR806-specific CAR T cell product infusions
Endpoint domain: Adverse events/effects
Primary endpoint: Absolute and Relative power in distinct frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Processed EEG index (PSI; patient state index)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean frequency and 95% spectral edge frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Burst suppression ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of Participants With Measles Seropositivity 56 Days Post-vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants With Rubella Seropositivity 56 Days Post-vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of accurate, mistaken and miss detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Contrast detection threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of prostate patients with comedo-type necrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Adherence to meditation program
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: changes in gut microbiota
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Prevalence of difficult airway cases
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants with Identified and Potential Clinically Important Risks
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Platelet function apoptosis markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in Platelet function activation markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Successful Attempts to Restore EAD(P) Patency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: etanercept levels in the blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in Implant stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in vertical bone height
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in marginal bone level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Major cardiovascular events (MACCE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maximum tolerated dose (MTD) of IV plerixafor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dose limiting toxicity (grade 3 or 4 nonhematologic toxicity)
Endpoint domain: Adverse events/effects
Primary endpoint: Phoneme Perception Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficiency of haemodialysis at 1 year
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Incidence of major adverse vascular events (MAVE)
Endpoint domain: Adverse events/effects
Primary endpoint: Word Retrieval Accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative Rate of Progression-Free Survival by Week 48 for ET+ART vs. PTX+ART
Endpoint domain: Mortality/survival
Primary endpoint: Cumulative Rate of Progression-Free Survival by Week 48 for BV+ART vs. PTX+ART
Endpoint domain: Mortality/survival
Primary endpoint: Force distribution measurement (FDM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Timed-up and go test (TUG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Five Times Sit to Stand Test (FTSTS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PD-1, TIM-3, CTLA4 expression levels on CD4/CD8 lymphocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Chronification of headache
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Peripheral Blood Mononuclear Cells (pBMCs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Serum Neurofilament Light Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in relative abundance of gut microbiome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Uncorrected Near Visual Acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiac related events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Anxiety Sensitivity
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in SDQ Emotional Problems
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Clinical resolution of bulbar conjunctival injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical resolution of watery conjunctival discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Group attendance
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of participants with angiostrongylosis A. cantonensis
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with angiostrongylosis A. costaricensis
Endpoint domain: Adverse events/effects
Primary endpoint: Red blood cell survival
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Pain magnitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Achieving ACR20 Response at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Percentage of Participants Achieving ACR70 Response at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Local control (LC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Control of Brain Disease (CBD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in cognitive skills
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Routine laboratory tests per patient-day
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Independant Observers' Perception of Expressed Emotions
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Objectively recorded physical activity level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC of Octreotide after CAM2029 injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ctrough of Octreotide after CAM2029 injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of Octreotide after CAM2029 injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quadriceps muscle mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Mean Serum Concentrations (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Viral Load-time Curve (VL-AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: qRT-PCR Peak Viral Load
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: KOOS Score overall
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: WOMAC Score overall
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VAS (Visual analog scale, pain score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle fatigue: Change of muscle twitch
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle fatigue: Change of dynamic force control accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tumour size change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Bleeding events (major or non-major)
Endpoint domain: Adverse events/effects
Primary endpoint: Sleep Disordered Breathing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: survival data
Endpoint domain: Mortality/survival
Primary endpoint: Self-reported sexual risk taking
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Patient Reported Outcomes Measurement Information System - Anxiety Short Form (PROMIS-ASF)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Patient Reported Outcomes Measurement Information System - Depression Short Form (PROMIS-DSF)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Cytokine profile (Th1, Th2, Treg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Safety measured by Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of patients reporting discomfort during or immediately following SAN021 application
Endpoint domain: Adverse events/effects
Primary endpoint: Patients achieving a Physician's Global Assessment of clear or almost clear
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Two Year Survival
Endpoint domain: Mortality/survival
Primary endpoint: Implant Migration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiac Resynchronization Therapy Responder Status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Need for supplemental physician-delivered bolus of local anesthetic
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Rate of patients achieving and maintaining LDPV targets
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Muscle size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in Muscle strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Rate of Confirmed Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in peak grip force
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vaginal laxity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composition of thrombi aspirated during acute myocardial infarction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Diagnosis-related difference in EEG or TMS measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Prognosis-related EEG or TMS measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Diagnosis-related changes in EEG or TMS measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Prognosis-related changes in EEG or TMS measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Laboratory Abnormalities Associated with Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Recommended phase II dose (RP2D) of vorolanib plus pembrolizumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recommended phase II dose (RP2D) of vorolanib plus nivolumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration Versus Time Curve From Time 0 Extrapolated to Infinity (AUC[0-inf])
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Density of intraepidermic nervous fibres
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of symptoms on the BSI 18 and the PFB-K
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity rating (0-8) of regulatory problems in infants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence and severity of fatigue
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Muscle Size Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Safety of MS-553
Endpoint domain: Adverse events/effects
Primary endpoint: Percent of Patients With Tumor Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Posterolateral spinal fusion rate at one-year follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Rate of (serious) adverse events related to spinal fusion procedure
Endpoint domain: Adverse events/effects
Primary endpoint: Major end organ dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: First alteration of the CTG's reactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: First perception of fetal movements by the mother
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: AUCt of Candesartan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of Amlodipine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCt of Amlodipine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adjusted rate of spinal imaging
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Length of hypertrophic scar(s) and keloids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: rate of UCB engraftment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rate of leukemia free survival
Endpoint domain: Mortality/survival
Primary endpoint: rate of overall survival
Endpoint domain: Mortality/survival
Primary endpoint: Area Under the Plasma Concentration Versus Time Curve [AUC(0-t)]
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in the number of MSCs in the knee
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: parameters resulting in disease susceptibility and severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Complete Eradication of Intestinal Metaplasia at 12 Month
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Complete Eradication of Dysplasia at 12 Month
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Complete Histological Clearance of Intestinal Metaplasia at 24 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Cerebral Oxygenation Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Two Minute Walk Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tissue Levels of Calcitriol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Detectability of Calcitriol Levels in Tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Safety of t-VNS® stimulation
Endpoint domain: Adverse events/effects
Primary endpoint: Feasibility of t-VNS® stimulation
Endpoint domain: Resource use
Primary endpoint: Effectiveness of t-VNS® stimulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: changes of alanine transaminase (ALT, U/L)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: number of participants with alanine transaminase (ALT) increasing over 3 folds of upper limit normally (ULN)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Total knee implant positioning
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Passive knee extension test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Neutrophil Gelatinase-associated Lipocalin (NGAL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: % of grade I/II and grade III/IV toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: MABS clearance from respiratory samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cardiac rhythm abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: QT length
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Crohn's disease activity index (CDAI) scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Knee Society Score (KSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Running cadence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in trough plasma concentrations of clozapine and norclozapine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Normalized FEV1 AUC0-12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Sum of Pain Intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes